ArticlePLOS digital health2026
Large language models as versatile predictive engines for notifiable infectious diseases.
Article in PLOS digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate forecasting of infectious disease cases and deaths is crucial for public health decision-making. Traditional statistical and machine learning approaches may be challenged by complex temporal patterns and heterogeneous surveillance data. We evaluated large language models (LLMs) for infectious disease forecasting. We collected monthly reported cases and deaths data from China National Notifiable Diseases Surveillance System (NNDSS) from January 2009 to February 2025, and monthly reported cases from the United States NNDSS from 2016 to 2023, covering 79 notifiable infectious diseases and 111 forecasting tasks. We evaluated seven models: four statistical models (ARIMA, TGARCH, EGARCH, ETS), two machine learning models (XGBoost, LSTM), and an LLM-based regression model built on Qwen-2.5-3B and fine-tuned using Low-Rank Adaptation (LoRA). Performance was assessed using mean absolute error (MAE), root mean squared error (RMSE), and mean absolute percentage error (MAPE). We used Friedman tests and Nemenyi post-hoc comparisons versus the LLM, reporting mean-rank differences (ΔR; > 0 indicates better LLM ranking). In pooled analyses, the Friedman test indicated significant heterogeneity across models (χ² = 26.24, P < 0.001). Nemenyi comparisons showed positive ΔR for all baselines against the LLM, with significance only in the XGBoost-LLM comparison (ΔR = 0.72, P < 0.001). By category, significant positive ΔR for all baselines against the LLM was observed in zoonotic infections (XGBoost: ΔR = 1.42, P < 0.001) and intestinal infections (TGARCH: ΔR = 1.28, P = 0.012; EGARCH: ΔR = 1.98, P < 0.001), whereas blood-borne infections showed LLM inferiority (ETS: ΔR=-2.29, P = 0.011; XGBoost ΔR=-2.86, P < 0.001). Geographically, positive ΔR was significant in China (XGBoost: ΔR = 0.80, P = 0.007), while the U.S. stratum was not significant (χ² = 9.04, P = 0.171). By outcome, between-model differences were detectable for case-forecasting (χ² = 20.72, P = 0.002; XGBoost: ΔR = 0.73, P = 0.005), with no detectable differences for death (χ² = 9.30, P = 0.158). In conclusion, LoRA fine-tuned LLM showed performance broadly comparable to statistical and machine learning models, with significant positive ΔR mainly observed in case-forecasting and in zoonotic and intestinal infectious diseases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.